The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2019 | Maximizing the effectiveness of oral therapies in lymphoid cancers: research gaps and unmet needs
Loretta Nastoupil, MD, University of Texas MD Anderson Center, Houston, TX, discusses the research gaps and unmet needs in oral therapies for lymphoid cancers, and how these can be addressed in order to maximize their effectiveness. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
